November 28, 2021

NasdaqNewsUpdates

Complete News World

COVID-19: 3rd dose of Pfizer / Bioentech vaccine with 95.6% efficacy

The tertiary clinical trial, conducted for “10,000 people over the age of 16”, showed “95.6% relative efficacy” and a “positive safety profile”.

“These are the first results of a randomized test performance for the booster of the Govit-19 vaccine,” the two companies said.

This study was carried out although the “delta variation is the main strain” during this period.

“These results once again demonstrate the usefulness of boosters in our efforts to protect people from this disease,” Albert Powerla, CEO of Pfizer, was quoted as saying in a statement.

The average age of participants was approximately 53 years.

The results will be submitted to regulatory authorities “as soon as possible,” they added.

According to some studies, many countries have already approved the administration of a booster dose against the corona virus to boost the immunity of those who have been vaccinated.

In the United States, experts at the U.S. Pharmaceuticals Agency (FDA) have been recommending a third Pfizer / Biotech dose since the end of September for some people at risk, such as those over 65 years of age.

“Available data indicate a weakening of the immune system in some people who have been fully vaccinated,” said Janet Woodcock, FDA’s Acting President.

In Europe, the Pharmaceutical Company (EMA) approved Pfizer / Biotech’s third dose policy for people over 18 in early October, allowing states to more accurately select eligible populations.

France, for example, began administering this booster dose to certain types of people: older (six months after vaccination) and those with weakened immune systems.

Other governments have gone further: in Israel, five months after vaccination, the third dose is available from the age of 12.

See also  "If he can change the delta variation ..."

However, the substance of the third dose has revived the problem of inequality between rich and poor countries, while access to the first dose of the vaccine is very low in some parts of the world, especially in Africa. Both levels in particular are very effective against severe forms of the disease.